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Advances in next-generation sequencing (NGS) techniques, including whole exome 
sequencing, have facilitated cost-effective sequencing of large regions of the genome, 
enabling the implementation of NGS in clinical practice. Chronic kidney disease (CKD) is 
a major contributor to global burden of disease and is associated with an increased risk of 
morbidity and mortality. CKD can be caused by a wide variety of primary renal disorders. 
In about one in five CKD patients, no primary renal disease diagnosis can be established. 
Moreover, recent studies indicate that the clinical diagnosis may be incorrect in a 
substantial number of patients. Both the absence of a diagnosis or an incorrect diagnosis 
can have therapeutic implications. Genetic testing might increase the diagnostic accuracy 
in patients with CKD, especially in patients with unknown etiology. The diagnostic utility 
of NGS has been shown mainly in pediatric CKD cohorts, while emerging data suggest 
that genetic testing can also be a valuable diagnostic tool in adults with CKD. In addition 
to its implications for unexplained CKD, NGS can contribute to the diagnostic process 
in kidney diseases with an atypical presentation, where it may lead to reclassification 
of the primary renal disease diagnosis. So far, only a few studies have reported on the 
diagnostic yield of NGS-based techniques in patients with unexplained CKD. Here, we 
will discuss the potential diagnostic role of gene panels and whole exome sequencing in 
pediatric and adult patients with unexplained and atypical CKD.
Keywords: end-stage renal disease, exome sequencing, diagnostic utility, genetic testing, kidney disease
INTRODUCTION
Chronic kidney disease (CKD) affects over 850 million individuals worldwide, and is associated 
with an increased risk of morbidity and mortality (Go et al., 2004; Gansevoort et al., 2013; Hill et al., 
2016; Jager et al., 2019) and a high burden in terms of quality of life and costs (Smith et al., 2004; 
Baumeister et al., 2010; Eriksson et al., 2016; Nguyen et al., 2018). Recent predictions by the Institute 
of Health Metrics and Evaluations indicated that by 2040 CKD will be the fifth cause of life years lost 
on a global scale (Foreman et al., 2018).
CKD is defined as decreased renal function [an estimated glomerular filtration rate (eGFR) 
lower than 60 ml/min/1.73 m2] or the presence of kidney damage, for 3 months or longer, 
irrespective of the underlying cause (Levey et al., 2011). According to the Kidney Disease 
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Improving Global Outcomes (KDIGO) guidelines, CKD can be 
classified into six stages based on eGFR (Table 1) and into three 
categories based on albuminuria (Table 2) (KDIGO, 2013). The 
first stages of CKD are often clinically silent and most patients 
start developing symptoms in stages 4 and 5, hampering the 
early diagnosis of CKD.
A positive family history is reported by 24–34% of patients 
with CKD, and familial clustering is a common phenomenon 
in patients with end-stage renal disease (ESRD) (Akrawi et al., 
2014; Skrunes et al., 2014; Connaughton et al., 2015). This 
indicates that, during the diagnostic workup of a CKD patient, 
the possibility of a hereditary cause cannot be neglected. This is 
supported by the fact that monogenic mutations are frequently 
found in early-onset CKD and that inherited kidney diseases are 
a common cause of ESRD in both adults and children (Devuyst 
et al., 2014).
Approximately 17% of patients with ESRD do not have a 
primary renal disease (PRD) diagnosis, and are therefore labeled 
as CKD with unknown origin. Furthermore, in many patients the 
primary diagnosis is inaccurate (Hoekstra et al., 2017). Making 
a correct diagnosis in these patients may have therapeutic 
implications. For example, a genetic mutation predisposing 
to atypical hemolytic uremic syndrome (aHUS) may provide 
crucial therapeutic possibilities with the availability of specific 
monoclonal antibodies targeting the complement system (Zuber 
et al., 2012). Moreover, a genetic diagnosis may be of pivotal 
importance for family counseling and in the setting of kidney 
transplantation, particularly when living-related donation is 
involved (Aymé et al., 2017).
A recent study in a cohort of CKD patients, of whom 65% had 
ESRD, demonstrated that a molecular diagnosis can be derived 
with next-generation sequencing (NGS) in approximately one in 
ten adults (Groopman et al., 2018). Since unexplained diseases 
have a higher risk of a genetic origin, it is likely that the proportion 
of patients in whom a molecular diagnosis can be identified is 
even larger when considering patients with unexplained CKD, or 
those with an atypical presentation. However, genetic testing is 
currently only performed in a minority of these patients.
NGS-based techniques are thus likely to improve the 
diagnostic accuracy in patients with CKD of unknown origin. 
It could also improve patient care, since NGS-based testing has 
the potential to identify the cause of CKD in an early stage of 
the disease, which allows timely intervention to delay or prevent 
development of ESRD. However, given the novelty of the 
technique, the value of NGS-based multi-gene panels and whole 
exome sequencing for these patients in clinical practice remains 
to be demonstrated.
In this review, we will discuss the utility of NGS-based testing 
in CKD patients with childhood-onset and adult-onset disease. 
Subsequently, we will focus on the potential role of NGS in the 
diagnostic workup of adult patients with an unknown PRD.
PREvALENCE AND CAUSES OF CHRONIC 
KIDNEY DISEASE
The global prevalence of CKD is 13.4%, with a higher prevalence 
in women compared to men and in patients over 70 years of age 
(Mills et al., 2015; Hill et al., 2016). Data on trends in the prevalence 
of CKD over the past decades are conflicting (Coresh et al., 2007; 
Aitken et al., 2014; Murphy et al., 2016), and the prevalence of 
CKD varies widely across countries (Bruck et al., 2016; de Grauw 
et al., 2018). For example, in Europe the prevalence estimates 
for CKD stage 1–5 vary from 3.3% in Norway, to 10.4% in the 
Netherlands, and 17.3% in north-eastern Germany (Bruck et al., 
2016; de Grauw et al., 2018). CKD prevalence may even vary 
within one country (Zhang et al., 2012). There are many factors 
which can partially explain the reported differences in prevalence 
between and within countries. Healthcare organization and 
policies in prevention and screening programs for CKD and 
its risk factors may vary substantially between countries. Other 
factors include, but are not limited to, communicable diseases, 
variations in laboratory methods, environmental factors like diet 
and toxins, ethnicity, genetic susceptibility, and differences in the 
prevalence of CKD risk factors like diabetes, hypertension and 
obesity (Jha et al., 2013; Agyemang et al., 2016; Stanifer et al., 
2016; Glassock et al., 2017; Webster et al., 2017).
While hypertension and diabetes are the leading CKD 
causes in Western countries, other common causes include 
glomerulonephritis and inherited forms of CKD (Jha et al., 
2013; Mallett et al., 2014). Interestingly, hypertension is not 
only a cause of CKD, but it can also occur as a result of CKD. 
Therefore, it can sometimes be difficult to determine which 
occurred first (Hamrahian and Falkner, 2017). It could thus 
be possible that some CKD patients with the PRD diagnosis 
"hypertensive nephropathy" have a different disease etiology, 
with hypertension being rather a consequence than the primary 
cause of the disease. In clinical practice, isolated essential 
hypertension rarely leads to ESRD, in contrast with, for example, 
malignant hypertension.




1 >90 Normal or high
2 60–89 Mildly decreased
3a 45–59 Mildly to moderately decreased
3b 30–44 Moderately to severely decreased
4 15–29 Severely decreased
5 <15 Kidney failure
GFR, glomerular filtration rate; eGFR, estimated glomerular filtration rate. Based 
on KDIGO guidelines (KDIGO, 2013).





1 <30 <3 Normally to mildly increased
2 30–300 3–30 Moderately increased
3 >300 >30 Severely increased
ACR, albumin-to-creatinine ratio. Based on KDIGO guidelines (KDIGO, 2013).
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A hereditary form of CKD can be found in approximately 
10% of the adult CKD population, comprising both patients with 
ESRD and patients with pre-dialysis kidney disease (Devuyst 
et al., 2014; Mallett et al., 2014). Compared to adults, children 
with CKD are more likely to have a hereditary form of CKD. 
Current estimates are that at least 15–20% of early-onset CKD, 
that is before 25 years of age, is caused by a genetic form. It is 
also estimated that nearly all children who progress to ESRD 
have an inherited form of CKD (Devuyst et al., 2014; Vivante 
and Hildebrandt, 2016). The most common inherited kidney 
diseases seen in the pediatric and adult populations are likely to 
be different from each other. For instance, autosomal dominant 
polycystic kidney disease (ADPKD) usually presents in 
adulthood, while nephronophthisis is more prevalent in children 
(Hildebrandt, 2010).
The number of ESRD patients with an unknown PRD 
diagnosis is increasing. In the Netherlands, the prevalence of 
ESRD of unknown etiology is 17% (Hoekstra et al., 2017). Similar 
percentages are found elsewhere in Europe (Kramer et al., 2018). 
Patients with an unknown PRD would benefit from an earlier 
diagnosis, which could permit early intervention to reduce the 
risk of cardiovascular complications and slow down or prevent 
the progression of CKD.
NEXT GENERATION SEQUENCING
Genetic testing can have an important role in accurately 
diagnosing PRD in cases that have a higher risk of an inherited 
form of CKD; for example patients with familial CKD, early-
onset CKD, an unusual disease course, or patients with an 
unknown cause of CKD (Vivante and Hildebrandt, 2016). 
One of the benefits of genetic testing is that it can identify 
the cause of disease regardless of disease stage, contrary to 
diagnostic renal biopsies that often fail to reveal a diagnosis 
in very early or late stages of the disease (Renkema et al., 
2014; Stokman et al., 2016). Moreover, genetic testing is non-
invasive and can shorten the diagnostic odyssey. Identification 
of a genetic diagnosis can play an important role in family 
planning, options for kidney transplantation, targeted 
surveillance of extra-renal features and can guide treatment 
and genetic counseling (Adams and Eng, 2018; Nestor et al., 
2018; Armstrong and Thomas, 2019). Counseling and genetic 
testing can also be of importance for relatives of the patient 
with genetic CKD. Identification of a genetic risk variant 
in otherwise healthy relatives can make them eligible for 
monitoring and early intervention to prevent progression of 
CKD and its complications, such as cardiovascular disease. In 
addition, it can exclude the relative for living kidney donation 
as to reduce the risk of future CKD.
Diagnostic genetic testing has benefited from advances in 
NGS, which has enabled cost-effective sequencing of large regions 
of the genome (Bick and Dimmock, 2011; Petersen et al., 2017). 
NGS, or massively parallel sequencing, allows simultaneous 
sequencing of multiple genes associated with a particular 
phenotype (gene panels), all 20,000 protein-coding genes (whole 
exome-sequencing), or the entire genome (whole genome 
sequencing) (Adams and Eng, 2018; Groopman et al., 2018). 
Each approach has its own advantages and limitations. Gene 
panels often have a higher sequencing coverage and depth than 
whole exome sequencing (WES) or whole genome sequencing 
(WGS), resulting in a greater diagnostic yield (Xue et al., 2015). 
However, the coverage and depth of NGS-based techniques varies 
depending on the capture systems used (Chilamakuri et al., 2014; 
Shigemizu et al., 2015; García-García et al., 2016). Coverage and 
depth of a system will also change over time as new updates and 
techniques become available, such as capture free WGS. It is thus 
important to select a suitable system.
Gene panel testing reduces the risk of incidental findings, 
being designed to only include a pre-selected subset of genes. 
Disadvantages of gene panels are that they need to be regularly 
updated to include newly discovered genes and the inherent 
requirement of a correctly interpreted clinical context, in order 
to avoid an inappropriate gene panel to be performed (Prakash 
and Gharavi, 2015; Groopman et al., 2018).
In contrast with gene panels, WES sequences all the protein-
coding genes of the genome and is thus not limited to a preselected 
set of genes. This allows a more flexible analysis compared to 
gene panels and the opportunity to identify new causative genes. 
Furthermore, WES data can be stored for future reanalysis as new 
genes are discovered and variants are reclassified (Groopman 
et al., 2018; Jayasinghe et al., 2018). Although WES sequences 
the entire exome, it is possible to only target a specified subset 
of genes with an in silico panel (targeted WES). This approach 
gives similar results as gene panels, but has the advantage that 
the original WES data can be “opened” for further analysis if new 
genes are discovered or if a causative variant cannot be identified 
in the initial analysis (Preston et al., 2017; Jayasinghe et al., 2018). 
Because of these advantages, most of the current diagnostic gene 
panels are based on targeted WES.
An important issue when performing WES is the possibility 
of detecting incidental findings, which are causative variants not 
related to the primary purpose for genetic testing. For example, 
when a genetic variant that predisposes to cancer is identified 
in a patient undergoing WES for hereditary kidney disease, this 
finding could not only have consequences for the patient (for 
instance intensified cancer screening or preventive surgery), 
but also for the relatives of the patient. The identification of a 
genetic risk variant for cancer can also influence treatment. 
Kidney transplant recipients have an increased risk of developing 
cancer, which can be partly attributed to immunosuppressive 
therapy. To minimize the risk of developing cancer, reduction 
of immunosuppression or other treatment options should be 
considered in transplant recipients with a genetic predisposition 
for cancer. There is, however, no consensus about when to report 
an incidental finding.
Another drawback of WES is that not all genomic regions are 
equally covered and regions with high guanine-cytosine (GC) 
rich content, copy number variants, and high sequence homology 
with pseudogenes may be missed (Xue et al., 2015). For example, 
WES is of limited use in diagnosing ADPKD, which is caused by 
mutations in PKD1 and PKD2. The PKD1 gene has a high degree 
of sequence homology with six pseudogenes, which complicates 
variant identification (Ali et al., 2019).
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Some of the limitations of WES can be addressed by WGS. 
For instance, WGS can identify copy number variants and has 
a more complete per base coverage compared to WES (Belkadi 
et al., 2015; Wu et al., 2016). WGS has the same advantages as 
WES, but has the additional benefit of being able to sequencing 
nearly all types of genetic variations in both the coding and non-
coding regions of the genome (Taylor et al., 2015; Wu et al., 2016; 
Lionel et al., 2018). For instance, WGS was able to identify a 
genetic variant in 86% of patients with ADPKD. This suggest that 
WGS can discriminate between the original PKD1 gene and the 
pseudogenes (Mallawaarachchi et al., 2016).
Other studies have reported that the diagnostic yield of WGS 
is higher than WES in a variety of disorders and that WGS can 
identify a causative variant in 20–40% of the patients in whom no 
genetic cause could be identified with WES (Gilissen et al., 2014; 
Ellingford et al., 2016). Nevertheless, WGS is not commonly 
used in clinical practice. This could be due to the costs and time 
associated with WGS, the requirements for data analysis and data 
storage, and the complex interpretation of unknown variants, 
especially intronic and other non-coding variants. However, it 
is likely that the capability to interpret variants in noncoding 
regions of the genome will improve over time. This, together 
with an expected decline in sequencing costs, will increase the 
advantages of WGS in the future (Lionel et al., 2018).
It is important to recognize that all forms of NGS-based 
testing have common limitations. For example, all NGS-based 
techniques were unable to detect causative variants in MUC1 in 
six unrelated families with autosomal dominant tubulointerstitial 
kidney disease. It was likely missed due to the highly repetitive 
GC-rich sequence and the variant was only identified by long-
range polymerase chain reaction and molecular cloning (Kirby 
et al., 2013). NGS-based testing is furthermore of limited value 
in most patients with acquired diseases and the translation of 
genetic findings to clinical practice may be challenging (Stokman 
et al., 2016). In addition, the social, ethical, and legal concerns 
of genetic testing cannot be neglected (Guay-Woodford and 
Knoers, 2009; Clarke, 2014).
Some limitations of NGS are caused by the short-read lengths 
that are used to maintain high coverage and depth. A new 
technique, long-read sequencing, may overcome some NGS-
specific limitations. Long-read single molecule platforms offer 
the ability to directly evaluate many difficult or even previously 
unsequenceable regions of the genome, such as repetitive 
elements, non-targeted structural variant breakpoints at base-
pair resolution, pseudogene discrimination, and epigenetics 
(Mantere et al., 2019). In the future, long-read sequencing based 
WGS could thus increase the diagnostic yield in patients with 
genetic CKD and give more patients a (correct) PRD diagnosis. 
Because of the advantages of genetic testing in general, and 
specifically the advent of NGS in the past decade, genetic testing 
is becoming increasingly relevant in clinical practice. However, 
the interpretation of variants remains a challenge with both WES 
and WGS.
Most studies on genetic testing in the field of nephrology are 
restricted to a research setting (e.g., cohort studies), and so far 
little is known about its diagnostic utility in clinical practice.
NEXT-GENERATION SEQUENCING IN 
CHILDREN WITH CHRONIC KIDNEY 
DISEASE
The most common causes of renal disease in children are 
congenital anomalies of the kidney and urinary tract (CAKUT), 
glomerulonephritis, steroid-resistant nephrotic syndrome 
(SRNS) and renal ciliopathies (Harambat et al., 2012; Becherucci 
et al., 2016). These renal diseases can all have a genetic etiology. 
Reports show that in approximately 20% of adolescents with 
early-onset CKD a monogenic cause of disease can be identified 
(Devuyst et al., 2014; Vivante and Hildebrandt, 2016). The high 
contribution of genetic causes in pediatric CKD is underlined by 
the fact that almost all children who progress to ESRD have an 
inherited form of CKD.
Extensive genetic research has been done in the pediatric 
CKD population, although data obtained in the clinical practice 
setting remain scarce. For example, a recent study investigated the 
diagnostic yield of targeted WES in a pediatric kidney transplant 
recipient cohort. The authors included children irrespective of 
clinical PRD diagnosis, and identified a causative variant in 34 of 
104 (32.7%) of patients (Mann et al., 2019). They found a higher 
diagnostic yield in patients with a positive family history for 
CKD, patients with extra-renal manifestation or with a history of 
consanguinity (Mann et al., 2019).
Other studies examined the diagnostic yield of NGS-based 
testing in pediatrics cohorts with a specific phenotype. For 
example, with NGS a genetic cause was identified in 55–80% of 
patients with Alport syndrome and in 21–25% of patients with 
nephronophthisis-related ciliopathies (Fallerini et al., 2014; 
Moriniere et al., 2014; Schueler et al., 2016). In patients with 
CAKUT, gene panels identified a causative variant in 2.5–6% 
(Hwang et al., 2014; Kohl et al., 2014), whereas targeted WES 
identified diagnostic variants in 5–14% of patients with CAKUT 
(Bekheirnia et al., 2017; van der Ven et al., 2018).
The diagnostic utility of targeted WES has also been addressed 
in SRNS, where a diagnostic variant was found in 11.1–29.5% of 
patients (Sadowski et al., 2015; Bierzynska et al., 2017; Tan et al., 
2018; Warejko et al., 2018).
Gene panels identified a causative variant in 16.8–20.8% 
of patients with childhood onset nephrolithiasis, which is 
significantly higher than the adult-onset setting where a genetic 
cause was identified in 11.4% (Halbritter et al., 2015; Braun 
et al., 2016). In comparison, targeted WES in patients with 
nephrolithiasis with onset before the age of 25 years identified a 
diagnostic variant in 29.4%. According to the authors, the higher 
diagnostic yield can be attributed to a younger age of onset, the 
inclusion or more familial cases, and presence of consanguinity 
(Daga et al., 2018).
The nephrolithiasis studies show that the clinical characteristics 
of patients can influence the diagnostic yield. The study design 
(sample size, number of genes sequenced, and whether patients 
are recruited from tertiary hospitals or specialized centers) can 
likewise affect the diagnostic yield. In addition, most studies have 
been conducted in patients predominantly of European ancestry 
and the result may therefore not always apply to other ethnic 
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groups. The results from the mentioned studies can therefore not 
always be generalized to the broader CKD population.
The data from the abovementioned studies are mostly obtained 
in a research setting. However, the potential diagnostic utility of 
targeted WES has also been shown in a clinical practice setting. 
Offering targeted WES to families of children with familial 
CKD led to an overall diagnostic yield as high as 46% (Mallett 
et al., 2017). These findings highlight the diagnostic potential of 
NGS-based testing in pediatric patients with early-onset CKD. 
It also underlines the need for further research in a diagnostic 
setting, to further define the position of NGS-based diagnostics 
in clinical practice.
NEXT-GENERATION SEQUENCING 
IN ADULTS WITH CHRONIC KIDNEY 
DISEASE
Genome-wide association studies (GWAS) and GWAS meta-
analyses have identified several common variants in genetic loci 
associated with CKD, including variants in UMOD, SHROOM3, 
solute carriers, and E3 ubiquitin ligases, as reviewed elsewhere 
(Cañadas-Garre et al., 2019). Despite the common genetic risk 
variants and the relatively high prevalence of genetic causes of 
CKD in adults, the role of NGS diagnostics in clinical practice 
has been limited compared to the pediatric population. A 
possible explanation is that genetic testing has traditionally been 
considered to be more successful in children compared to adults 
(Mallett et al., 2017). However, targeted WES in familial CKD 
in a diagnostic setting showed similar diagnostic rates among 
children (31 of 67 patients, 46.3%) and adults (27 of 68 patients, 
39.7%) (Mallett et al., 2017). There were, however, significant 
differences in diagnostic yield between adults and children for 
certain phenotypes such as aHUS (17% in adults vs. 67% in 
children) (Mallett et al., 2017).
These findings were confirmed by a recent study from Ireland. 
Targeted WES showed comparable diagnostic rates among 
pediatric onset CKD (20 of 50 patients, 40%) and adult onset 
CKD (35 of 85 patients, 41%) (Connaughton et al., 2019). The 
similar overall diagnostic rate between adults and children seems 
in contrast with previous observations that showed an inverse 
correlation between proband age and the chance of identifying 
a genetic cause for a specific inherited type of kidney disease 
(Sadowski et al., 2015).
Subsequent studies have further highlighted the diagnostic 
potential of NGS in an adult CKD population. For example, 
targeted WES in a broad CKD population identified diagnostic 
variants in 307 of 3,315 (9.3%) patients (Groopman et al., 2018). 
This cohort consisted of 91.6% adults (over 21 years of age) and 
64.7% of the patients had ESRD. In the 307 patients with a genetic 
diagnosis a subsequent analysis was done with a phenotype-
specific gene panel. This resulted, at most, in a genetic diagnosis 
in 136 of 307 (44.3%) patients (Groopman et al., 2018).
Several studies have investigated the diagnostic rate of NGS-
based testing in adults with specific renal phenotypes. For 
example, genetic testing identified causative variants in 14% of 
adult-onset SRNS and gene panels found diagnostic variants 
in 11.4% of adult-onset nephrolithiasis. In both studies a lower 
genetic yield was associated with a higher proband age (Santín 
et al., 2011; Halbritter et al., 2015).
The diagnostic yield of NGS-based testing in patients with no 
clear PRD or with a family history of CKD is likely higher than 
in the overall CKD population. Indeed, a pilot study in adults 
with familial or unexplained CKD demonstrated that targeted 
WES identified a causative variant in 22 of 92 (24%) patients. 
These encompassed 13 different genetic disorders and influenced 
medical management in 21 of 22 patients (Lata et al., 2018).
As mentioned before, the results from these studies cannot 
always be generalized to the broader CKD population due to 
ascertainment bias. For instance, the authors of the pilot study 
mention that the generalizability of the results to the general 
CKD population is limited by a small sample size and the fact 
that the cohort is enriched for familial or suspected genetic CKD 
(Lata et al., 2018).
 These studies confirm the importance of NGS-based testing in 
adults with CKD. Increased awareness for the possibility of genetic 
testing in adults could help to provide more patients an early and 
specific diagnosis, aiming to prevent progression of CKD and its 
complications. However, the diagnostic yield of genetic testing 
may be lower in patients who are older at disease onset. More 
research is needed to determine the effect of age at onset on the 
yield of genetic testing in the context of CKD; such studies will 
direct guidelines towards cost-effective implementation of NGS-
based testing. Moreover, the diagnostic yield in CKD is currently 
limited by the fact that in many cases the underlying cause is 
polygenic in nature; the development of polygenic risk scores may 
further improve diagnostic yield in the future.
NEXT-GENERATION SEQUENCING TO 
RECLASSIFY THE PRIMARY RENAL 
DIAGNOSIS
Most inherited kidney diseases have a high degree of genetic 
heterogeneity and are associated with a wide range of phenotypes 
(Kalatharan et al., 2018). This can make it challenging to 
distinguish certain kidney diseases based on clinical presentation, 
and may lead to misdiagnosis.
The emergence of NGS has enabled a more precise 
differentiation between overlapping phenotypes based on a 
genetic diagnosis. In some cases, the genetic diagnosis can lead 
to reclassification of the PRD diagnosis in individual patients. 
For example, it may be difficult to discriminate between Alport 
syndrome, mesangial proliferative glomerulonephritis (MPGN), 
and primary focal segmental glomerulosclerosis (FSGS) based 
on clinical presentation and renal biopsies (Yao et al., 2012). 
However, the distinction between these diseases is of great 
importance with respect to treatment and clinical outcomes. 
Genetic studies have shown that patients with Alport syndrome 
have been misdiagnoses as MPGN (Adam et al., 2014). In 
addition, multiple studies have shown that patients with FSGS 
were reclassified as Alport syndrome based on mutations found 
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in COL4A3, COL4A4, and COL4A5 (Adam et al., 2014; Gast et al., 
2016; Yao et al., 2019). Genetic testing can distinguish between 
different etiologies in heterogeneous diseases and prevent an 
incorrect diagnosis.
Another example of reclassification has been illustrated in a 
report describing the use of WES to obtain a genetic diagnosis 
(Choi et al., 2009). In a cohort of patients with suspected Bartter 
syndrome, WES identified no candidate variants in Bartter-
associated genes but instead found a variation in SLC26A3. 
Variants in this gene are associated with chloride diarrhea, and 
clinical follow-up confirmed the diagnosis of chloride diarrhea 
in these patients (Choi et al., 2009).
Moreover, in a recently published analysis from the 
iGeneTrain consortium, it was found that 0.5% of patients with 
adult-onset ESRD had a full gene deletion of the NPHP1 gene. 
This percentage increased to almost 1% when only the patients 
of 18–50 years at ESRD onset were considered (n = 24). Full 
gene deletions of NPHP1 are associated with nephronophthisis, 
the most common genetic cause for ESRD in children. Of the 26 
patients with a full NPHP1 gene deletion, only 3 had a correct 
clinical PRD diagnosis of nephronophthisis (Snoek et al., 2018). 
This is not surprising, since nephronophthisis had previously 
been considered to result in ESRD exclusively at child age.
Other studies have also reported on the reclassification of PRD 
diagnosis based on genetic findings, albeit in cohorts with limited 
sample size. For example, Lata et al. identified a genetic diagnosis 
in 22 of 92 adults with CKD, and in two of these patients the 
kidney disease was reclassified. The reclassification of diagnosis, 
from FSGS to autosomal dominant Alport syndrome and to 
autosomal recessive Alport syndrome, had direct consequence 
for clinical management (Lata et al., 2018). Furthermore, in a 
study by Connaughton et al. targeted WES identified a molecular 
diagnosis in 42 of 114 families with CKD, and in 9 of these 42 
families the initial CKD diagnosis was changed based on genetic 
findings (Connaughton et al., 2019).
Similarly, in a pediatric cohort consisting of 79 
consanguineous or familial cases with a suspected diagnosis 
of nephronophthisis, targeted WES identified causal variants 
in 63% of cases. While in 64% of these families the suspected 
diagnosis was confirmed, in a noteworthy 36% of these families 
a different molecular diagnosis was found. The CKD diagnoses 
in these families were reclassified as Alport syndrome (8%), 
CAKUT (6%), renal tubulopathies (16%), autosomal-recessive 
polycystic kidney disease (4%), and auto-immune nephropathy 
(2%) (Braun et al., 2016). These finding show that (targeted) WES 
can provide a correct diagnosis in genetically and phenotypically 
heterogeneous diseases. The above findings demonstrate that it 
is very likely that a subset of CKD patients has a misdiagnosis 
and that with the increased availability of genetic testing more 
primary diagnoses will be reclassified.
NEXT-GENERATION SEQUENCING IN 
UNEXPLAINED CHRONIC KIDNEY DISEASE
WES facilitated the molecular diagnosis and PRD reclassification 
in both pediatric and adult cohorts and informed prognosis, 
therapy, and counseling in these patients. Moreover, WES has 
the potential to resolve cases with unknown etiology (Need 
et al., 2012; Hauer et al., 2018) and could thus be a valuable 
analytical tool in the diagnostic process of patients with an 
unknown PRD or in patients who have an atypical/nonspecific 
clinical presentation.
The diagnostic value of WES in CKD patients with 
unknown etiology is illustrated by a pilot study by Lata et al, 
including 16 patients who had CKD with unknown etiology 
(Lata et  al., 2018). A causative variant was identified in nine 
of these patients, indicating a diagnostic yield of 56%. The 
established diagnoses consisted of a variety of nephropathies, 
including CHARGE syndrome, X-linked and autosomal 
forms of Alport syndrome, HNF1B-associated disease, Dent’s 
disease, and autosomal dominant tubulointerstitial kidney 
disease (Table  3). In addition to providing a kidney disease 
diagnosis for these patients, the genetic diagnosis influenced 
medical management. Clinical implications included a change 
in therapy (for example avoidance of immunosuppressive 
therapy), screening of at-risk family members, screening for 
extra-renal features, and optimal selection of living related 
kidney donors (Lata et al., 2018).
Another study in which the diagnostic value of WES in 
patients with undiagnosed CKD is demonstrated is the recently 
published study of Groopman et al. Targeted WES provided a 
molecular diagnosis in 48 of 281 (17.1%) patients with CKD 
of unknown origin. The diagnostic yield in this group was the 
second highest in this study, the yield was only higher in patients 
with a clinical diagnosis of congenital or cystic renal disease 
(23.9%) (Table 3) (Groopman et al., 2018). In addition, the 
authors found that nephropathy of unknown origin, a family 
history of CKD, and clinical diagnosis of congenital or cystic 
renal disease were independent predictors of yielding a genetic 
diagnosis (Groopman et al., 2018).
A recent study by Connaughton et al. also reported on the 
diagnostic value of targeted WES in patients with unexplained 
CKD (Connaughton et al., 2019). A causative variant was 
identified in 16 of 34 (47%) families with CKD of unknown origin. 
The newfound diagnoses consisted, among others, of X-linked 
and autosomal forms of Alport syndrome, Dent’s disease, 
Fanconi anemia, Wolfram-like syndrome, nephronophthisis, 
and nephrocalcinosis/nephrolithiasis. The diagnostic yield 
in the unexplained CKD family group represented 38% of the 
identified molecular diagnosis in this study (16 of 42 families) 
(Connaughton et al., 2019) (Table 3).
The diagnostic value of gene panels in patients with 
undetermined ESRD is demonstrated by Ottlewksi et al, who 
tested 50 patients on the kidney transplantation waiting list 
with undetermined CKD (Ottlewski et al., 2019). The renal 
gene panel, consisting of 209 genes associated with ESRD, 
identified a causative variant in 6 of 50 (12%) these patients. 
The genetic diagnosis consisted of X-linked and autosomal 
dominant forms of Alport syndrome and familial FSGS. The 
identification of a genetic diagnosis in six patients significantly 
reduced the proportion of patients with unexplained ESRD 
on the kidney transplant waiting list (Ottlewski et al., 2019) 
(Table 3). 
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The dissimilarities in diagnostic yield between these studies 
likely result from differences in sample size, different inclusion 
criteria, NGS approach, and different selection of genes. The 
study of Lata et al. included only patients with familial or 
suspected genetic CKD (Lata et al., 2018). This enrichment 
for genetic diagnosis could explain, together with the limited 
sample size, the high yield. Groopman et al. included CKD 
patients irrespective of diagnosis or family history (Groopman 
et al., 2018), while Connaughton et al. included mostly CKD 
patients with a positive family history or extra-renal features 
and only a small proportion of CKD patients who had neither 
familial CKD nor extra-renal features (Connaughton et al., 
2019). The study by Ottlewski et al. also has a limited sample 
size, but it is not clear what the proportion of patients with 
familial CKD or extra-renal features is. However, five of six 
patients in which a genetic diagnosis was identified had a 
positive family history (Ottlewski et al., 2019). In addition, it 
is the only study using gene panels instead of targeted WES. 
The diagnostic yield is thus dependent on the characteristics 
of the included patients and the study design. This can make 
it difficult to make comparisons between different studies, 
especially when some patient characteristic are unknown. 
The findings above highlight the diagnostic value of NGS 
based testing for patients with unexplained CKD, especially 
in patients with early-onset or familial CKD. Further research 
is needed to explore the diagnostic utility of WES for CKD of 
unknown etiology in larger cohorts and in a clinical setting. 
Such studies should guide the position of NGS diagnostics 
in the work-up of patients with unknown PRD, by revealing 
subpopulations with the highest diagnostic yield that may be 
preferentially offered this diagnostic testing.
CONCLUSION
NGS, including gene panels and WES, shows promising results 
as a diagnostic tool in both pediatric and adult CKD cohorts. In 
a considerable proportion of patients, particularly in those with 
familial CKD (~40%), NGS has the potential to resolve CKD cases 
with an unknown etiology. NGS also enables the reclassification 
of PRD diagnoses. Counseling on the potential implications of 
a positive test result is essential, particularly for WES, given the 
possibility of incidental findings. Although further research is 
needed to determine which subpopulations will have the highest 
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ADTKD, autosomal dominant tubulointerstitial kidney disease; AS, Alport syndrome; CHARGE, coloboma, heart defects, atresia choanae, growth retardation, genital 
abnormalities and ear abnormalities; CKD, chronic kidney disease; ESRD, end-stage renal disease; FSGS, focal segmental glomerulosclerosis; NA, not available; NPHP, 
nephronophthisis; SD, standard deviation.
*Age at presentation from the total cohort, not specific for unexplained CKD subset.
**Patient characteristics from the total cohort, not specified for unexplained CKD subset.
†Number of patients with a positive family history for CKD in the total cohort, not specified for unexplained CKD subset.
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diagnostic yield, we foresee an expanding role for NGS-based 
diagnostics in clinical nephrology in the coming years.
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